The Androgen Society 2nd Annual Meeting
March 21 - 22, 2019 | Hilton New Orleans Riverside | New Orleans, LA
Testosterone (T) deficiency, also known as hypogonadism, has a wide variety of effects in men and women. Although T therapy has been available since the 1930s, it is only within the last 15-20 years that treatment has become relatively common, leaving many key clinical questions unanswered or in evolution. Clinical research to guide evidence-based practice continues to provide new information of considerable importance to patients, physicians, and researchers. However, there is limited opportunity for physicians to familiarize themselves with these evolving diagnostic and therapeutic approaches outside of CME events.
The goal of the annual meeting of the Androgen Society is to promote excellence in research, education, and clinical practice with regards to T deficiency and its treatment. Formats for educational sessions will include lectures, reviews of large randomized and observational studies, debates, and panel discussions. Many controversial issues will be addressed, including the use of testosterone in men with prostate cancer, the postulated cardiovascular risks and benefits of T therapy, the use of T therapy in women, and the growing field of research showing important effects of T therapy on metabolic conditions, especially diabetes. Practitioners will gain enormously from attending this meeting, with benefits ranging from practical tips on patient management to an understanding of molecular pathways by which testosterone influences endothelial and pancreatic beta cell function.
At the conclusion of the Meeting, attendees will be able to:
- Employ an evidence-based algorithm for approaching the diagnostic and therapeutic management of men with testosterone deficiency.
- Identify novel management options for T deficiency.
- Identify the role of regenerative medicine in the management of T deficiency.
- Identify controversies in testosterone therapy including cardiovascular risk and use in prostate cancer patients.
- Describe the origin of the concern that testosterone is risky for men with prostate cancer.
- Identify which patient is a candidate for treatment based on various published guidelines.
- Discuss how to approach testosterone deficiency in women.
- Explain the effects of testosterone deficiency and treatment on fat cells, muscle cells, and obesity.
- Discuss the basis for the controversy regarding cardiovascular risk with testosterone therapy.
- Identify which patients with prostate cancer may be considered reasonable candidates for T therapy.